NasdaqGS - Nasdaq Real Time Price USD

Hologic, Inc. (HOLX)

Compare
80.33 +0.62 (+0.78%)
As of 11:16 AM EDT. Market Open.
Loading Chart for HOLX
DELL
  • Previous Close 79.71
  • Open 79.90
  • Bid 80.28 x 400
  • Ask 80.44 x 400
  • Day's Range 79.85 - 80.54
  • 52 Week Range 64.02 - 84.67
  • Volume 230,503
  • Avg. Volume 1,568,682
  • Market Cap (intraday) 18.658B
  • Beta (5Y Monthly) 0.99
  • PE Ratio (TTM) 27.42
  • EPS (TTM) 2.93
  • Earnings Date Nov 7, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 88.29

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

www.hologic.com

6,990

Full Time Employees

September 30

Fiscal Year Ends

Recent News: HOLX

View More

Performance Overview: HOLX

Trailing total returns as of 8/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

HOLX
12.43%
S&P 500
17.24%

1-Year Return

HOLX
6.52%
S&P 500
26.93%

3-Year Return

HOLX
1.44%
S&P 500
24.01%

5-Year Return

HOLX
66.45%
S&P 500
94.91%

Compare To: HOLX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HOLX

View More

Valuation Measures

Annual
As of 8/27/2024
  • Market Cap

    18.51B

  • Enterprise Value

    18.63B

  • Trailing P/E

    27.20

  • Forward P/E

    18.08

  • PEG Ratio (5yr expected)

    1.24

  • Price/Sales (ttm)

    4.80

  • Price/Book (mrq)

    3.74

  • Enterprise Value/Revenue

    4.67

  • Enterprise Value/EBITDA

    15.31

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.59%

  • Return on Assets (ttm)

    6.45%

  • Return on Equity (ttm)

    13.85%

  • Revenue (ttm)

    3.99B

  • Net Income Avi to Common (ttm)

    701.5M

  • Diluted EPS (ttm)

    2.93

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.45B

  • Total Debt/Equity (mrq)

    51.69%

  • Levered Free Cash Flow (ttm)

    757.96M

Research Analysis: HOLX

View More

Company Insights: HOLX

Research Reports: HOLX

View More

People Also Watch